High druggability with robust patent protection to enable accelerated development cycles, reduced costs, and sustained competitive advantage.

The platform achieves targeted delivery to specific disease-affected organs. This not only ensures therapeutic efficacy but also provides better safety profiles, achieving an optimal balance among efficacy, safety and convenience.

Rapid Formation of Novel Targeted Prodrugs: Based on validated active substances and targets, the platform can quickly generate novel targeted prodrugs that offer significant improvements in pharmacokinetics/pharmacodynamics or safety. It efficiently produces candidate compounds with high clinical development value.

Effective chemical structure modifications are used to improve various drug properties, including physicochemical characteristics, delivery and transport efficiency, enzyme selectivity, and compound stability. AI technology is employed to enhance precision and efficiency.

The CureGene-X1 platform is a fully integrated, modular system engineered to streamline and accelerate drug development from target identification to clinical candidate. Moving beyond conventional vaccine applications, it serves as a versatile solution for therapeutic development by enabling precise in vivo expression of functional proteins or peptide antigens. This platform holds the potential to deliver revolutionary treatments across a broad spectrum of diseases, including infectious diseases, autoimmune disorders, cancer immunotherapy, and genetic metabolic disorders.